OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 11000 participants.
Also called NCT07136012
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 11,000 participants
- Sponsor
- Registry
-
NCT07136012
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia, Canada, China
- Registry status
- Recruiting
Technical summary
Registry record NCT07136012. Randomized; double masking; primary purpose treatment. Start 2025-08-22 (actual); primary completion 2031-10-20 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And Lipoprotein(a) Reduction to Prevent First Major Cardiovascular Events
- Condition
- Cardiovascular Disease
- Intervention (Drug)
- Olpasiran
- Intervention (Drug)
- Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct07136012- Content hash
cc64fc60f138f15d3885be401a8fcbb0595eaf7c6440335d78b096e920f492f0